GlassScriptPhysician profile
Dilip D Kachare
NPI 1477549939
$3,260.56
in general payments reported to CMS, 2019-2025
24 companies · $289 in 2025
The $289 reported for 2025 was more than what a typical Adolescent Medicine (Internal Medicine) provider received nationally (typical 2025 total: $165).
See the full distribution for Adolescent Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $783 · 2020: $248 · 2021: $523 · 2022: $436 · 2023: $418 · 2024: $561 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,269.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $584.14 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $482.51 | 2020-2023 | Verquvo |
| Phathom Pharmaceuticals, INC. | $362.15 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $227.43 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $174.58 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $172.92 | 2019-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $171.81 | 2019-2022 | |
| Lilly USA, LLC | $161.21 | 2021-2025 | Zepbound |
| Gilead Sciences, INC. | $134.74 | 2024 | Biktarvy |
| Biohaven Pharmaceuticals, INC. | $125.00 | 2021 | |
| Amarin Pharma, INC. | $112.62 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.35 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $81.72 | 2019-2022 | |
| Glaxosmithkline, LLC. | $73.60 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $62.39 | 2020-2024 | Farxiga |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $56.78 | 2022 | |
| Pfizer INC. | $56.16 | 2022-2023 | |
| Dexcom, INC. | $31.46 | 2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $26.29 | 2022 | |
| Sanofi-Aventis U.S. LLC | $15.04 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $15.00 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $14.92 | 2023 | Inpefa |
| Sk Life Science, INC. | $11.41 | 2021 | |
| Allergan, INC. | $11.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dilip Kachare listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.